HC Wainwright & Co. Reiterates Buy on Tempest Therapeutics, Maintains $47 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Joseph Pantginis has reiterated a Buy rating for Tempest Therapeutics (NASDAQ:TPST) and maintained a price target of $47.
October 10, 2024 | 5:42 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated a Buy rating for Tempest Therapeutics, maintaining a $47 price target, indicating confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $47 price target by a reputable analyst suggests a positive outlook for Tempest Therapeutics. This can boost investor confidence and potentially lead to a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100